+ All Categories
Home > Documents > Teste Dublu Orb

Teste Dublu Orb

Date post: 03-Apr-2018
Category:
Upload: lilucamp
View: 243 times
Download: 0 times
Share this document with a friend

of 20

Transcript
  • 7/28/2019 Teste Dublu Orb

    1/20

    RevolutionaRy technology that

    communicates with the Body

    Sponsored by: Supplement to:

    ALTERNATIVE THERAPIESI N H E A L T H A N D M E D I C I N E

  • 7/28/2019 Teste Dublu Orb

    2/20

  • 7/28/2019 Teste Dublu Orb

    3/20

    ALTERNATIVE THERAPIES Supplement 1Ft Rx Crar Artr DaTa f Ctt

    TABLE OF CONTENTS

    2 ATaeofSkeptcsmandDscovery:CanHoographc

    StckersReayAffectOurPerceptonofPan?

    Atul M. Gupta, MD

    3 ARandomzedDoube-bndPacebo-controedStudy

    ontheEffectvenessofChargedHoographcChpsfor

    theReductonofPan:APotStudy

    Atul M. Gupta, MD

    5 EffectvenessoftheCeAuraWeghtManagementSystem

    onWeghtReducton:ANoveMethodMilton E. Kirkwood, DO; Atul M. Gupta, MD; Roxanne

    Edrington, DC, CCN; Marc Langas, DC; Warren Longmire,MD; David Potts, DC

    6 ARandomzedDoube-bndPacebo-controedStudy

    ontheEffectvenessofChargedHoographcChpson

    RhnosnustsnAduts:APotStudy

    Atul M. Gupta, MD

    9 ADoube-bndPacebo-controedRandomzedStudy

    ontheEffectofChargedHoographcChpsonSeep:A NoveMethod

    Andrew Campbell, MD; Al Johnson, DO

    11 RandomzedSnge-bndPacebo-controedMutcenter

    StudyoftheEffectsofHoographcCX2Wrstbands:A

    PotStudy

    Atul M. Gupta, MD; Jelunder Clark, MD

    publisheD by innovision pRoFessionAlmeDiA As A supplemenT To

    Alternative Therapies in Health and Medicine

    edtr--CfAnDRew CAmpbell, mD

    maa edtrCRAig gusTAFson

    Crat DrctrRAnDy pAlmeR

    grac DrmARgAReT vAneChAuTe

    i prfa mda, ic.1270 eaa idtra Rad, st 190

    eaa, mn 55121T: (877) 904-7951Fax: (651) 344-0774

    w: .atrat-tra.c

    prdt ad gr prDiCK benson

    vc prdt & CFoJohn benson

    Crcat DrctrniCK CollATos

    iT maarsAm bhATT

    Adtrat AtatKelly smAll

    AdvertsngSaes

    DAviD benson(651) 251-9623

    [email protected]

    A rt rrd. Rrdct r art tt cc rtt r frAlternative Therapies in Health and Medicine

    rtd a.

    DiSClAiMER:Theauthors,edtors,pubshers,andsponsorofthssuppe-

    ment have exercsedreasonabecareto verfydrugnamesand doses, theresutsofexpermentaworkandthecncandngspubshednthsjour-

    na. The opnonsexpressedare thoseofthe authors andnotnecessary

    thoseoftheedtorsorpubshers.Someoftheproductsreferredtonths

    suppementmaynotbeavaabenacountresnwhchthejournasava-

    abe,ortheymaybeavaabewthadfferentformuatonorwthdfferent

    condtons of use and/or cams than those dscussed n the artces. As

    aways,theutmateresponsbtyfortheproperuseofdrugsmentonedn

    the journa and nthe nterpretatonofpubshedmateraseswththe

    medcapracttoner,asdoesobservanceofocareguatoryapprovas,and

    theedtorsandpubsherscanacceptnoabtywhatsoevernrespectofany

    camfordamagesarsngthereof.Peasenformtheedtorsofanyerrors.

  • 7/28/2019 Teste Dublu Orb

    4/20

    2 ALTERNATIVE THERAPIES supplement edtra

    pa tckr. . . ra?

    i a t adt ta ract a r taktca t da f card rac c art rtd t .

    m a Dr At m. gta, ad i a tCf mdca offcr (Cmo) f CAra, llCt ca tatarkt t a c. i i cd a tat jr frktc t Cmo a f -dd ad tt. Ttrt f t attr tat i t t t cc t jtf kt-cad t d t a t cc tat td a tr tat i cd

    t r.i xrc rd a trt rct frradr k t ar r at atra rdct, a a tad crtca aa f t cc d t rdct. irdr t f drtad tt, t tart t a tt f ackrd.

    A a aatc ca t utd stat, fra tra- at, Arda, k, acctr, r tr-t a t rat t car fct a ta xtt. Tfactr actd dc t k d dca-c tra- fr ctar tra: t eatr fc f r ad ra dr t arac dc a ar

    tr ta rcr t ak t.Aftr ct a tr ra rr ad a r-c dc rdc, i fd tat t 40 t 50 r ac kt a rc r (eR) dd t rd t fr tractc c a ar. w t ractc f t t eR, ifd a artr ad d a ad ca dcractc. A r fc, trat act ad crc a tt arcrt dcat. T a rt rfa xrctd f tradta dc, ad t a a-r.

    A t ractc a c ttr, a ra frdad tr akd t tr a card rac c arktd a ca cad CAra. i k t at -rac c ad a r . T at t i dd a -t at.

    Dt rctac, i a trd t rct f da ct atra a t r dcfrt. T ratd dc ia at l3-l4 crta dcard tf fr t t t t eR, adi xrcd tat rf t t rac c. i a t kt-ca, r, a i k tat t ac ffct ca a a ar art r rct. Aftr a, t d ac at t d .s i t t t r t f tr r t t tckr cdra ffct fr a ctc tadt ratr ta tt-a. m trr t, r, a r t frd tat

    t rac c ad t tc d t d td t ctc aat.

    i ra cdctd t f t radzd d-d a-c-ctrd tra cdd t t cat ad a aazd t rt. T d t at tt addta tra, tf c aar t cat a . Dt t ratr f crat t t t, i cd r ar tt rt. it a t tat i t ad ktc ad cad t CAra t t a f rad t rd t frd ad ca. Atr 10 t ad fr i ca

    t Cmo f t cat aazd ad c r .m tr f ktc, ctc crt, ad adat a c f j a tr arr da dcr t rt xrc CAra rdct. T a a radrdd, a 54 ctr tr t CAra rdct frrf. i a rd t ar tr ad t data t ad kfrard t ar at r xrc a .

    Tak ,

    At m. gta, mDCf mdca ofcr

    CAra, llC

    ATaeofSkeptcsmandDscovery:CanHoographcStckersReayAffectOurPerceptonofPan?

    CeAuraproductsaresodforearnng,sef-mprovement,andsmpereaxaton.Nostatementcontanednthswrt-ngandnonformatonprovdedbyanyCeAuraempoyeeorretaershoudbeconstruedasacamorrepresentaton

    thattheseproductsarentendedforusenthedagnoss,cure,mtgaton,treatment,orpreventonofdseaseoranyother medca condton. The nformaton contaned nthswrtngsdeemedtobebasedonreabeandauthor-tatvereport.However,certanpersonsconsderedexpertsmaydsagreewthoneormoreofthestatementscontanedhere.CeAuraassumesnoabtyorrsknvovedntheuseoftheproductsdescrbedhere.Wemakenowarranty,expressed or mped, other than that the matera con-formstoappcabestandardspeccatons.

  • 7/28/2019 Teste Dublu Orb

    5/20

    ALTERNATIVE THERAPIES Supplement 3pa std

    Atul M. Gupta, MD,sanemergencyphyscan,practcngwthNaturalvng,inc,nBuffton,SouthCarona.

    Disclosure: Dr Gupta is the chief medical ofcer of the company that pro-vided the charged holographic chips for this study, CieAura of Las Vegas,

    Nevada.

    pa a fcat c at r ad affctr Arca ta dat, art da, ad cacrcd. i a ar td f Arca 20 ar addr, r ta 26% rrtd tat t ad ad a r- t a fr r 24 r. T dd t cd

    act a.1 Arxat 33% f t a dcrd t ada, trfr t tr fct f da f.2 T aacc ct t utd stat tatd at $600 . Tr cd t c, t rdctt, ad at car x-.3 pa t cd ad ca f rk at d t adca cdt ad rt r ta 50 t rkdaaa.1 hr, t f a t, t nata ittt fhat ddcat ta 1% t rarc a.

    mckta a rt fr jr, r, rtttra, ad rk-ratd r. it affct t , c, a-t, td, ad r ad ca act r crc, fca, r df-f. T a tratt fr ckta a ct faac ad acta a a rt tra, t tr-

    da ataatr dr (nsAiD) r ccxa-2 (CoX-2)dr a cd .4 od ad atcat ar a

    rrd fr t d t rd t rt ad cd tra-.5 otr tratt dat, c a acctr, ca ctr-ca tat, ca tra, ccata tra, adara tra ca t rdc a. T arc fr drtra fr d t drat ckta a crrt dr- t rarc.METHOD

    T td ctd ta f 533 adt artcat r-td t ar a cat at t wt A w adRa fact Cart, st Cara. partcat rrcrtd a tar a xca fr fr rac ca art f t 1-k tra. ic a t ddt a a cc d art, ad artcat cat cdd ad-ac, tradar jt drdr, dr, ck, ack, k,ad ak a. Frtrr, crc a a ara rrtd t r, a a att t tc at fr cdt c a raa, crc artrt,ad drat jt da. patt cr f 4 tr 7 tAdra makk pa sca (Amps, Ta 1) r td t ar-tcat.

    of t 533 artcat, 267 r radzd t r A, ad266 r radzd t r b. T 267 artcat r A

    ARandomzedDoube-bndPacebo-controedStudyontheEffectvenessofChargedHoographc

    ChpsfortheReductonofPan:APotStudyAt m. gta, mD

    Objectve T jct f t td t aat t ffctf card rac c t rdct f a r- t d t drat ckta a.Methods i a, 486 adt artcat t d t dratckta a r radzd t r A r rb. T ackt f rac c r ad A r b.o ackt f c a card r act, ad t tr acard r ac. hrac c r ct r a dcrd tradta C dc,c ckd adr affct t at f dda.bt t artcat ad t atr r dd. T artc-at ctd t Adra makk pa sca (Amps) att f t td ad 1 k atr at t ct ft td, ad t data r rcrdd ac t t atr.partcat ad t a a cr t 4 ad 7 t Amps

    t qaf fr t td. irt a t at a dcra f 3t r r t Amps. T atr dtratd trr act f t card rac c ad artt trct t t artcat.Resuts At t ct f t cd rcrd f trt 1 k aftr t rt rcrd f t Amps, t cda rk. gr A (246 artcat) ad rcd tcard rac c ad gr b t ac. gr Aad a 83% rt f tr a. gr b (240 artc-at) ad a 18% rt. T td ra tat tcard rac c ca a cat ad rdca adt. Frtr td ar dd t cra t c-tc ad dca kd rard t ffct fcard rac c aat a adt.

  • 7/28/2019 Teste Dublu Orb

    6/20

    4 ALTERNATIVE THERAPIES supplement pa std

    r rdcd t 246 t d f 1 k d t artcat fat rtr fr f- r fa t t rac c tr-t t k. T 266 artcat r b r rdcd t 240 frt a ra.

    A artcat d a ar c t ard t artcat t td, c ackdd tr drtad ad ct-t t c t t dcrd td fr t c fr ttd, a a t a tr a-r rdct r d-c dr t td. it a cdd a ra f at dcattat t tatr a t r fr a adr tc

    t fr f td atra, c a tt t ad.T rac c, rdd CAra f la va,

    nada, r ta acd artcat t atr, aa a mda. eac rac c ad a ad ack ad a-rd 2.3 c datr ad 2 t 3 cr tck. T -rac c r acd tr d f t ara f a (trac c tta). partcat r fr addta -rac c t trct t rac t rac c tr d t a fr ar wdda ad Frda f ta k. partcat r cd t rtac f dra-t. T r a trctd t t tak a tr dcat r

    t fr a fr t k f t td. partcat r t aa 1 k atr t f mda.

    partcat r akd t rat tr f a fr 1 t 10 t Amps rr t rac c act, c arcrdd t atr at t rt t ad t rcrdd aa at t1-k f- ad card t t rt Amps cr. o tadt t a cr t 4 ad 7 t Amps r cdd

    t td.

    incusonaryCrteraandExcusonaryCrteraicar crtra r t f: a r fa

    t t a f 25 ad 60 t a cr fr 4 t 7 tAmps. prat fa; att dcat, atdr-at, tc, dat, tat, r a dcat f akd; ad t a Amps cr f ta 4 r r ta 7r xcdd.

    RESUlTSAftr t data cct a ctd, t cd a rk:

    r A ad rcd t card rac c (ChC), adr b ad rcd t card rac c tat cttt-d t ac t td. irt a t at r tra Amps cr f ac artcat 3 t r r. nrt a a dcra f 2 r t Amps cr. of t246 artcat r A, 204 ratd a rt tr a(83%), ad 42 ratd cat dffrc (17%). of t 240 artc-at r b, 43 ratd a rt tr a (18%), ad197 ratd cat dffrc (82%) (Ta 2).

    DiSCUSSiONTr a d t utd stat fr ckta a

    rf fr r t d t drat a tat t dr ad.

    mdcat ad tr d ffct ar dctd ad cdd tPhysicians Desk Reference. it k tat acta caca r daa tak fr rd f t at d-a a c fd r ffr fr a. nsAiDar k t ca atrtta d6 ad CoX-2 dca-t a catd r cardacar ffct.7prcrt dr ar t cd t ad dr Arca.8prcrt akr ar a ajr ctrtr t dr dat.9

    T cc f ChC t d-d ac-ctrdtd dtrat t ffct f t td aatd t drat ckta a, ff a d fr a

    TABLE 1: Adra makk pa sca

    0 pa fr

    1 vr r aac: ccaa r t

    2 mr aac: ccaa tr t

    3 A t dtract

    4 Ca rd f ar ra d r

    rk t t dtract

    5 Cat rd fr r ta 30 t

    6 Cat rd fr a t f t, t cat t rk ad artcat ca actt.

    7 mak t dfct t cctrat, trfr t: y ca t fct t ffrt.

    8 pca actt r td: y ca rad ad crt ffrt; aa ad dzz t a factr f a.

    9 ua t ak: cr t r a ctra,ar dr.

    10 ucc: pa ak a t.

    TABLE 2: Rt f pa std

    gr T f hrac Crt partcat s prcta s partcat s prcta sC prdd sz scat scat n scat n scat

    irta irta irta irta

    A Card 246 204 83% 42 17%

    b ucard (ac) 240 43 18% 197 82%

    ascat rt a dd a a rdct Amps cr f 3 t r r. Amps cr ca f 2 t r r t cdrdcat.

  • 7/28/2019 Teste Dublu Orb

    7/20

    ALTERNATIVE THERAPIES Supplement 5

    Milton E. Kirkwood, DO,snprvatepractce,Pasadena,Texas,andsacncanstructor,UnverstyofTexasMedcaSchoo,Houston.Atul M. Gupta, MD,spresdent,Naturalvng,inc,practcesemergencymedcnenBuffton,SouthCarona,andschefmedcaofcerofCeAura,lasVegas,Nevada. Roxanne

    Edrington, DC, CNN,sacertedcncanutrtonstnprvatepractce,Webster,Texas.Marc Langas, DC,snprvatepractce,Tyer,Texas.Warren Longmire, MD,snprvatepractce,Htchcock,Texas.David Potts, DC,snprvatepractce,Pasadena,Texas.

    EffectvenessoftheCeAuraWeghtManagementSystemonWeghtReducton,ANoveMethod

    mt e. Krkd, Do; At m. gta, mD; Rxa edrt, DC, CCn; marc laa, DC; warr lr, mD; Dad ptt, DC

    Objectve ot a ajr dca r ad ctr-t t t r-cra ct dca car. or 60% f

    Arca ar rt. ot acatd t acrad rk f cardacar da, dat, artrt, adcacr. T dat, t t aat rra fa tac -tr rt. T CAra wt maatst crrat dt ad xrc rcdat adar atra, tc t; att ar a t ct t rcdat cra tr kd f ac- t ctr. T t tz r dc c-ct t rac tradra c acd ac-rr t. it a ak f ra ta t crar ad dcra att. T r f t td taat t CAra wt maat st ad f

    artcat t ar tr t ad c t r a14-k rd.

    Desgn A tctrd, cca tra crt td tCAra wt maat st.

    Partcpants o drd xt- fa ad 69 a,ra a fr 25 t 73 ad dr t at at 25d artcatd.Resuts A tta f 230 artcat a t 14-k tdad 200 ctd t td. partcat acd catt t a ara f 30 . partcat a t aara f 20 tta ar, t, ct, at, ad . nr d ffct r rrtd.Concuson T CAra wt maat st ffra ffct ad a atrat fr t rdct att.

    pa std/wt std Atract

    aaa atrat t dr. Tr ar cca r drd. ChC r affct t atra r a rdatr t d ar t acctr, c a dd tC r 3000 ar a. Acctr a t rda c-t t d d trt Aa ad a dtrt t rd. mr td ar dd t frtr xat f f t dat t rf f d t drat

    a adt.REFERENCES

    1. nata Ctr fr hat stattc. hat, utd stat, 2006. tt://.cdc./c/data//06.df. pd nr 2006. Accd octr 6, 2011.

    2. prt RK, uart C, Fr i, haa g. pat-ad r f a t utd stat:dffrc a t, Afrca Arca, ad hac jct. J Pain. 2004;5(6):317-328.

    3. Ctt Adac pa Rarc, Car, ad edcat, ittt f mdc, bard

    hat scc pc.Relieving Pain in America: A Blueprint of Transforming Prevention, Care,Education, and Research. wat, DC: nata Acad pr; 2011.

    4. ht Rh, Cqtt D, Cra bn, t a. Arac t aa ckta a: act-a, ccxa-2 tr, r tradta nsAiD? Can Fam Physician.2007;53(7):1177-1184.

    5. ba D, brt m, brdr g, t a. ptrat Aac Tra orata sr(pAThos): a ractc attr td 7 ctra/tr era ctr. Pain.2008;136(1-2):134-141.

    6. br Al, brk A, F gC, t a. erc ad fr r atrtta daad tr rat t nsAiD .Aliment Pharmacol Ther.1997;11(2):283291.

    7. h-Cx J, Cad C. Rk f carda farct att tak cc-xa-2

    tr r cta -trda at-aatr dr: at ad tdca-ctr aa.BMJ. 2005;330(7504):1366.

    8. stac A ad mta hat src Adtrat. Rt fr t 2009 natasr Dr u ad hat: v 1. tt://.a.aa./nsDuh/2k9nsDuh/2k9Rtp.df. sar f nata Fd. pd 2010.Accd octr 24, 2011.

    9. Ctr fr Da Ctr ad prt. utta Dr p t utd stat.tt://.cdc./hadRcratasaft/df/--rf.df. Accdoctr 6, 2011.

  • 7/28/2019 Teste Dublu Orb

    8/20

    6 ALTERNATIVE THERAPIES supplement s std

    Atul M. Gupta, MD,sanemergencyphyscan,practcngwthNaturalvng,inc,nBuffton,SouthCarona.

    Disclosure: Dr Gupta is the chief medical ofcer of the company that pro-vided the charged holographic chips for this study, CieAura of Las Vegas,

    Nevada.

    Arxat 24 adt ffr fr taa t utd stat.1 T t f tca fct, arc, at, r cca.2At 90% f a adt a ffrd fr t tr , ak t f t t c dca

    cdt.3 ifct f ra r actra r ar c, tra t at 7 t 10 da ad actra fct r.Ar ca ctrt t t. Fa t ad at

    ca ar rat. Fa t c r c r t dcc, dat, AiDs, ad ka.sk, cr, ad tr cca ca ctrt t t.

    st f t ar r.4 s f t t c- ar aa ct, dcrad f , ra aa,trat dcfrt, adac, at, faca rr ad tdr,a t r cr ad ca tt, c, ad fr.

    Fr t tratt f t, cta dcat cdattc, aa crtctrd, atta, ad dc-tat. 5,6 st c a ra, qrct, ad

    n-actct a d fr t tratt f t7 a a ta C.8,9 hr, ca cat, a k t att.10 hatc tratt f t ca ffct, ad td d tat r ta 80% f artcat ad catrt f tr t.11 Acctr ca a cafr t rf f t t.12

    METHODpartcat t td r att at wt A w

    ad Ra Cart, st Cara, r td t aar r t at t t f tr t. eac a rcrt-d a tar a xca fr fr rac c a artf t 1-k tra. A t qtar, dd ad rcrdd t atr ( Adx A), rd a a cr t. T q-tar rakd t artcat t t fr 1 t 10. A

    cr f 1 dcatd r d t, 5 dcatd drat -t, ad 10 dcatd r r t. partcat cr 4r r qad fr t td.

    A artcat d a ar c t ard t artcat t td, c ackdd tr drtad ad cttt c t t dcrd td fr t c fr t td,a a t a tr t-r rdct r dcdr t td. it a cdd a ra f at dcat tat ttatr a t r fr a adr tc tfr f td atra, c a tt t ad.

    ARandomzedDoube-bndPacebo-controedStudyontheEffectvenessofChargedHoographc

    ChpsonRhnosnustsnAduts:APotStudyAt m. gta, mD

    Objectve T jct f t td a t dtr tffct f card rac c (ChC) adtt t.Method Frt- adt artcat ca f tfr 2 t 3 k drat r radzd t r A r b.T ackt f rac c r ad A r b. oackt f rac c a card r act (ChC) adt tr a card r ac. hrac c r c t r a dcrd tradtaC dc, c ckd adr affct tat f dda. bt t artcat ad t atr rdd. A artcat r akd t ct a qt-ar rak tr t t at t f ttd ad 1 k atr at t ct f t td. Trak r rcrdd ac t t atr. partcat

    ad t a a cr f 4 rdr t qaf fr t td.irt a t at a dcra f 3 r r t trt-rt qtar. T rac c r -ta acd artcat aa a mda t atr.Resuts Aftr t data cct a ctd, t cd ark, ad r b ad rcd t ChC. T r da 92% cc rat t rf. i ctrat, t artc-at r A rcd t ac d a 10%cc rat, c ctt t t acctd ra fac ffct. i r A, 90% f artcat dtratd rf f t. T a cat dffrc ad tr-fr rt t rt tat ChC tra ca rdc t. Frtr td ar dd t cra tctc ad dca kd f ChC aat -t f t adt.

  • 7/28/2019 Teste Dublu Orb

    9/20

    ALTERNATIVE THERAPIES Supplement 7s std

    T ta 68 tr artcat r rad ad tr A r r b a atrat a ddt t tat c t ard t tak art t td. Card racc (ChC) r dtrtd t ac r. T dtrt ad d, a tr t atr r t att k tr tacta ChC r t card ac c r t r A rr b.

    eac r rd 34 artcat. gr A a rdcd t20 artcat t d f t k d t cac ttd trct r far t rtr fr f- aat. grb a rdcd t 25 artcat fr t a ra. T tta -r f artcat ctd t td a 45.

    A rac c tat ard 2 c 1 c a acdd t rt ar f ac artcat mda, ad a artc-at r t t addta rac c t trc-t t rac t rac c wdda ad Frda f ta k. partcat r trctd t atrat ar t -rac c act. T ara d t ar a k rdafr r tradta C dc. T artcatr a trctd t t tak a dcat r t frcd, ct, r r fr 1 k. partcat r ra-atd 1 k atr t f mda, at c t t -t qtar ( Adx b) a radtrd ad rcrdd t atr.

    1. D a a f t t? (pa cck)C R naa ecza

    wznaa ctpr f h / srt f ratitc ear fcthadacCt ttitc / atr s fctsrsz

    ptaa drbckd arFatp /t (cr) ____________________otr

    2. w ar r t at tr rt?A. yar rdb. wtr

    1. Dd t c rdc r t?y n

    2. u t a ca f 1 t 10 a fr, rat t rt f rt aftr t c fr t at 1 k. 1 - n t 2 - vr d t 3 - md t 4 - md t drat t 5 - mdrat t ccaa 6 - mdrat t frqt 7 - mdrat t ct 8 - sr t ccaa 9 - sr t frqt 10 - sr t ct

    3. Dd xrc a d ffct?y (pa xa t ct ct)n

    4. wd rcd t tratt t a frd r rat ad t a r?

    CommenTs:

    APPENDIX B: pt-tratt s Qtar

    C. srD. sre. Fa

    3. ha r ad ar jct?

    4. ha rcd crt (rd, trd, tc.)dr?

    5. D k?6. Ar tr a tacc kr r ?7. Ar tr a t r ?8. D a atr ak r d ctaat?9. wat trr r t?10. w d r t t ttr?11. ha k ttd; f at r t rt?12. wat r ccat?13. o a ca f 1 t 10, rat t rt f r /ar t. 1 - n t 2 - vr d t

    3 - md t 4 - md t drat t 5 - mdrat t ccaa 6 - mdrat t frqt 7 - mdrat t ct 8 - sr t ccaa 9 - sr t frqt 10 - sr t ct

    APPENDIX A: pr-tratt s Qtar

  • 7/28/2019 Teste Dublu Orb

    10/20

    8 ALTERNATIVE THERAPIES supplement s std

    incusonaryCrteraandExcusonaryCrteraicar crtra r t f: a r fa r

    t a f 25 t a 60 t a cr f 4 r ratr t tt qtar.

    prat fa; att tak atta, attc,aa ra, dctat, a dcat, crtctrd, at-fa, tra, a r, t, acctr, ta-

    C, r atc tratt fr t; ad t acr f ta 4 t t t qtar rxcdd.

    RESUlTSsccf rt f t a t at r t

    ra qtar cr f 1 t 10 f ac artcat 3 tr r. n rt a cdrd a a dcra f 2 r t qtar cr. Aftr t data cct a ctd, tcd a rk. gr A ad a ac, ad r bad rcd ChC. of t 20 artcat r A, t ratd art tr t (10%), ad 18 ratd -cat dffrc (90%). of t 25 artcat r b, 23 ratd art a (92%), ad t ratd cat dffrc(8%). T a cat d ChC tra r -t f t.

    DiSCUSSiONst a rat ad c dca cdt fd

    a fcat rcta f t at t utd stat.Accrd t td fr 2001, r $6 t aa dcat t trat aa ad cdt.13 T ct - r tda. st f t t c rafr rcr attc ad acct fr 12% f a rcrt.13

    Tr ar a r f rcrt dcat, r-t-ctrdcat, ad ctar ad atrat tratt frt.

    T d-d ac-ctrd t td dtratt ffct f ChC tra aat t t f -t. T td f t d r tr rd-a a dd t C r 3000 ar a; t ct t d tda Aa ad d d trt t rd. ChCr t d r tr t rda t t -cat d t t f t. T d r at rda t d t dt t at r rr-tat. T ffct f ChC tra ar r datd ratr ta

    datd. wt t act f a ChC d tar, t att t fr ra tadt: tr ar c-ca r dcat d; tr t t a r ra;tr ar d ffct r adr ffct. std t arr rf artcat ad r rd f f ChC ar dd t frtrxr t f f t td aat t -t f t.

    REFERENCES1. s Jh. st. Otolaryngol Clin North Am. 2004;37(2):x-x, 221-506.2. A Jb. ur rratr fct.Am J Med.2010;123(4 s):s16s25.3. para An, C Db. R f crrt d ratd t t da ad tratt

    f rt. Curr Opin Otolaryngol Head Neck Surg. 2008;16(3):226230.4. sa Rg, sctr sl, brt il, t a. T da ad aat f t: a ractc

    aratr dat.J Allergy and Clin Immunol.2005;116(6 ):s13-s47.5. Faaa me, ga Kp, vardaka KZ, D g, Karar De.

    Car f attc t ac fr tratt f act t: a ta-aa fradd ctrd tra.Lancet Infect Dis. 2008;8(9):543-552.

    6. l R, Kata R. T da ad aat f act ad crc t. Prim Care.2008;35(1):11-24, -.

    7. Ar bF, sda m, sdra C. Ctar ad atrat dc tar-.Laryngoscope.2001;111(8):1383-1389.

    8. grt hC, Jar K. T ffct f ta C rt ad r t tf r-dcd rratr fct.J Manipulative Physiol Ther.1999;22(8):530-533.

    9. Da Rm, Cakr eb, Trac b. vta C fr rt ad trat t c cd.

    Cochrane Database Syst Rev. 2000;(2):CD000980.10. g R, Catr ph, ert e. hra dc fr t tratt f rt: a tatc

    r. Otolaryngol Head Neck Surg. 2006;135(4):496-506.11. Adr m. efcac ad aft f a xd-cat atc tra fr t. Adv

    Ther. 1999;16(2):103-111.12. Rr e, lar pg, brkt o, st le, sta K. Car f tradta C

    acctr, a acctr at -act ad cta tratt fr cr-c t. Complement Ther Med. 2005;13(1):4-10.

    13. gr Cw, scr RJ. prac ad cc act f rt. Curr OpinOtolaryngol Head Neck Surg. 2001;9(1):8-10.

    TABLE 1: Rt f s std

    gr T f hrac Crt partcat s prcta s partcat s prcta sC prdd sz scat scat n scat n scat

    irta irta irta irta

    A ucard (ac) 20 2 10% 18 90%

    b Card 25 23 92% 2 8%a scat rt a dd a a rdct t qtar cr f 3 t r r. st qtar cr ca f 2t r r t cdrd cat.

  • 7/28/2019 Teste Dublu Orb

    11/20

    ALTERNATIVE THERAPIES Supplement 9s std

    Andrew Campbell, MD,smedcadrector,MedcaCenterforimmuneandToxcDsorders,TheWoodands,Texas.AlJohnson, DO,smedcadrector,JohnsonMedcaAssocates,Rchardson,Texas.

    Disclosure: Andrew Campbell, MD, is editor in chief ofAlternAtivetherApiesinheAlthAndMedicine.

    ectrcara a tat ctf t tat: Rem (rad t) ad nRem(-Rem) , c frtr aratd t fr df-frt ta. s ccca, t fr t Rem tadr t t. it tatd tat t ra a-

    t 20% ta t dd a ctr a.1 pr a acatd t t, fat, t 2 dat, rt, ada tr at r.2-4 s dfct ca affct datar, cd dat , ad ca ctrt t trc accdt.5

    prca ca f dfct cd ca , a,dr, aa, rt dr, axt, ad tr ad

    t f ac, dr, r tacc.6-10 T arc fr t rd fr dffct a fr ctr ad crrt t rarcd. Tr ar a r f dcat ad ratratt crrt aaa fr . T cd tc,at, ad ara rt. hr, t rd ca ttaca atd d ffct ad adr ract.9

    METHODi t td, accad att t a ra

    dc cc r akd f t d artcat a td. T r a fa r r frd f att

    rt t t cc. T artcat r crd fr dr-dr ad crd cdt ad d a ar ta a raf at f dr t artcat t td.

    T artcat r rac c (card -rac c [ChC] r card ac c) t r trr t t d fr 10 da, ac a c ac t tr tra ara. T 20 artcat rcd c radfr A r fr b fr a tta f 10 artcat frac . T at rfa ad artcat r d-d. o f t t ctad rac c tat rcard ctrca t a fra (ChC); t tr t rac. eac c ad a ad ack ad ard 2 c 2c ad 30 cr tck. T td f car t -rac c ad t fra tf ar rrtar t t a-factrr, harc Fm, sa, gra. T ert ssca (ess) a adtrd at t ad at t d f 10da. At t d f t td, t a ac a rk tra tat dr t td r b d ChC ad r A dac.

    incusonaryCrteraandExcusonaryCrteraicar crtra cad fr ad a 25 t 60.

    prat ; t a f-rt atd ctrcdc; kr; tak ta, dcat, atd-rat, tc, dat, tat, a dcat; ad tak ra rd fr , axt, r dr rxcdd, a r dr t a f 25 r r t a f 60.

    EpworthSeepnessScaeT ess a adatd a a f t fr t at 20 ar. 11

    it d t ar xc dat ad ratd aftr

    ADoube-bndPacebo-controedRandomzedStudyontheEffectofChargedHoographcChps

    onSeep:ANoveMethodAdr Ca, mD; A J, Do

    Objectves pr acatd t a r f atr, cd t, rt, ad t 2 dat.w t t dtr t fcac f card racc (ChC) adt artcat t erts sca.Methods T a a radzd d-d ac-c-trd t td. Tt adt, a 25 t 55, r rad-zd t rc ac r ChC fr 10 cct da. Tartcat r adtrd t ert s sca(ess) at t ad at t d f t 10 da.

    Resuts mart a t ess d a catrt t dcra f dat artc-at. T artcat rrtd tat t d t tdr ad t r ta a.Concuson u f ChC tra fr r a -cat ad af dcra dat adt.pac-ctrd, dd td t arr rt ardd t dtr t tr ffct f ChC ad dcra dat .

  • 7/28/2019 Teste Dublu Orb

    12/20

    10 ALTERNATIVE THERAPIES supplement s std

    t adtrat f a artcar tratt t dct r-t f t.12

    T artcat r ac a t f ar ad akd tf qt t a at rfa attdac rcrdd t ar:

    h k ar t dz ff r fa a t f tat

    rct t?1. stt ad rad2. watc Tv3. stt act a c ac (, a t r tatr)4. A a ar a car fr a r tt a rak5. l d t rt t aftr crctac

    rt6. stt ad tak t 7. stt qt aftr a c tt ac8. i a car td fr a f t trafc

    partcat r akd t rca ar r qt

    ad t f ca:n cac f dz: 0st cac f dz: 1mdrat cac f dz: 2h cac f dz: 3

    T cr fr t t qt r addd ttr t taa r. A r tad, a cr t 0 t 9 ra cdrd t ra t 6 t 8 ara. A cr t 10t 24 ra dcat tat xrt dca adc d t.11

    T artcat r trctd at rr drat ad ac t c t tra. T ara k tradtaC dc (TCm) a a rda fr . T artcatr dcatd t rdct f t ctratc d trdr.

    u ct t 10-da rd, t artcat rcrd fr d ffct ad arc ract. T r rad-trd t ess a at rfa. oc t rt r rcrdd,t cd fr t ac ChC a rad.

    RESUlTSRt d arc ract r d ffct. T ta

    ess rad a a cr f 12.6 t a da cr f 13. Trt tad aftr t 10 da d tat artcat rcac ad a a cr f 14 t a da cr f 14.5.

    partcat rc ChC tra ad a a cr f 4.3 t ada cr f 4.

    T rt dcat a rtat rt f ess crad dat t rcd ChC a cardt ac. T ChC ar a cat td fr t r-t f ad t aat f dat . i f tac f cca r tr tac, t tta t ad a dra f tt t ccr at d ffct r adrract a rtat factr. TCm r ta 3000 ar d.ChC r TCm rc ccr t d r ftr rda ar t acctr t xrt t ffct.

    Frtr ar ca td ar dd t xad t dca ad c-tfc kd f ChC tra fr r ad trt f dat .

    REFERENCES1. ittt f mdc. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem.

    wat, DC: T nata Acad pr; 2006.2. gtt DJ, pja nm, na Ab, t a. Acat f t t dat t

    ad ard c trac.Arch Intern Med. 2005;165(8):863867.

    3. Kck m, latta Z, marc-hrat e, t a. iard c trac drdr.PloS One.2010;5(3):9444.

    4. lraat Jm, gaat A. s ad rt: a ca fr t atc ratf t cardacar t. Circulation.2005;112(6):786788.

    5. ittt f mdc. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. wat, DC: T nata Acad pr; 2006. [[a a rf #1, dt t t arf tc, rf d rr]]

    6. Za, n. s ad dtrac: ca a ad cca cat.Cell Mol LifeSci. 2007;64(10):11741186.

    7. nata s Fdat. s Fdat. .fdat.r. Accd octr 7,2011.

    8. Trkadr C, watr As, h w. prdc t ad rt dr.Neurol Clin. 1996;14(3):629-650.

    9. nar Dn, st pl, ear CJ. s drdr. i: barkr lR, brt JR, Z pD,Fca Te, d. Principles of Ambulatory Medicine. 5t d. batr, mD: wa &wk; 1999:1314-1328.

    10. od ml, Fx Ch. Adt aa dr. Am Fam Physician. 1995;52(3):859-866,871-872.

    11. J mw. A td fr ar dat : t ert s sca.Sleep. 1991;14(6):540-545.

    12. hard Fm, pt DJ, strad JR. u f t ert s sca t dtratr t tratt t aa ct t ara rr att ttrct aa.Respir Med. 1995;89(9):617620.

  • 7/28/2019 Teste Dublu Orb

    13/20

    ALTERNATIVE THERAPIES Supplement 11wrtad std

    Atul M. Gupta, MD,sanemergencyphyscanpractcngnBuffton,SouthCarona,andthechefmedcaofcerofCeAura,lasVegas,Nevada.Jelunder Clark, MD,sMedcaDrector,WenessMedcne,Hampton,Georga.

    Disclosure: Harmonic FM, Inc, and CieAura, LLC, manufacture and mar-ket the CX2 Plus Wristband. Harmonic FM provided all equipment used

    for the testing and funded the test. Participants at Dr Clarks facility(Wellness Medicine, Hampton, Georgia) were given $20 and product sam-

    ples. Dr Lisa Marsh was paid for her time performing the trial evaluationand data recording at the Florida site. Participants at Dr Phillips HighSchool, Orlando, Florida, were given one CieAura CX2 Wristband.

    ertc d ar ratd r ra.1,2

    Tradta C dc (TCm) art tat td a atra attr f q tat crcat cacad rda. Q, traatd fr C, f-frc r r .

    T C dcrd q rk r 3000 ar a, adt atra t f rda r d crrat t t r-tc d. T rat ar t tat f t art ad td r tat f t ra ad t r t. wrrr rtrd a d r r t, fct rtrd ad t r a f ttr. T a ccta t t rda t. T rda ar t a fratra r f ad ccat. w cka arrd, fct rtrd.3,4

    TCm racttr tat t f ar frdrtd, ckd, r aacd q t tr t drda, a a dcc f q.5 T d rk ctt cct r t t ta ra, c, ad t;r, a tat f aac tat k r, cctrat, taa,ad ad ( ad a) at t rar ccr.3TCm ractc a art f tcq t adjt t crcat

    f q ad r aac. T tcq cd r,fd tra, ca tra r (q, ta c, ad trarta art tra), xt, t a, ad acctr.4,6

    CAra CX2 rtad, dd ar 2010, ar cardt a trc r fra dd cca t tzr . T rtad xtra trc r t tractt t d r d ad a rc f c cadtrat. T rc dcr t r f jcta t at t tract t ad affct t r f atr t-t ca tc t.5,7 T rtc car t t rt-ad tract t ad a t d t atra aac tf.

    baac t d dd r a tz t r r q t d.

    Dtrat f q r ar ar rac farta art. Ta c rfr t dtrat a tat f rtc a-ac a t a d.8 it a cad rt r acrt t art. w rtd, t cat ardr t t a rr,2,4,6 ad trfr, t tat a dcatr tat ca d d-trat rtc aac r tt rtc.

    nd rtd at cc acctr t a tatr cc rda.2,4 T CX2 rtad aac td rda ca c k acctr ad a t dt fct r fct. it t acctr t trt t tat t f, c tr fc t d adcra r, aac, trt, ad xt.

    ENERGYANDTHEBODYPhyscaCompostonoftheCX2Wrstband

    T CX2 rtad ad f c. T traart -rac c, arxat .5 .5 , ar ddd t trtad. eac c a t- ra ad f a t- 20 t 30 cr tck. T fra ad td f ft fra t t ra ar rrtar t harc Fm. Ara ca d c r frat ta tr dc tt a ftrt. oc fd t t rac c, t r-tc fra cat atrd. it ca rad a tr a-t. A rac c d d t data fr at at 50 ar. 9

    i- tt a a tat t rtad cact acd t 1 t 2 f t d. it ffct tcd. it d t a t acd drct t k. i-tt a a tat ffct f t rtad dtrratr t a t r. Fr tt r, rtad rd t td. hdrat a rtat factr rtadffct ca t r car fct. Tt artcatt rr dratd rr t ac tt.

    ANonchemcaMechansmT car t c, a trc r fra fd t a

    t- ra, c t rtd t a c rtad.T f rc ctrc atr, t cca.

    i tradta c, fr t f frc xt: a frc,ar frc, ctratc frc, ad rat. hr, rxrt r t at ra dcad a tat tr frc- d xt.2 Dcr t frc fa t t c f qatcac. itrc r, a d t rtad ttd, t t r10; a ra r rat

    RandomzedSnge-bndPacebo-controedMutcenterStudyoftheEffectsof

    HoographcCX2Wrstbands:APotStudyAt m. gta, mD; Jdr Cark, mD

  • 7/28/2019 Teste Dublu Orb

    14/20

    12 ALTERNATIVE THERAPIES supplement wrtad std

    t ara f qat cac.1 itrc r fd t trac c t t tt f crat a xtra a tffct ca ca t t d c tad f ctr.

    sc trc r cat ard drct, a dr-tad f t rc d t xtc a f. Fr tcc f t radr, a f t rtt cct f.

    CasscaPhyscsvsQuantumPhyscspc d t dcr r ad t rat. Tr ar

    t fdata ar c dr c rt. o Art et tr f ra ratt, c rd a trt-ca frark fr drtad t r t art f ca:tar, aax, ctr f aax, ad d t t xa- f t r tf. T tr qat cac, crd a trtca frark fr drtad t r t at f ca: c, at, ad atc artc ca ctr ad qark.11 T r ad qat f ar d tcar rk t t tr.11 Caca c t rdd et tr f ra ratt. Qat c

    t r f qat cac.Qat c da t t ar ta a at. iqat c, t qat rdct ar ar accratf t caca r ar t ad. T t qat rk xtr- fr rdct rt. A t r rk t ra qat rd ar t:

    (1) Tr ar t tr d, t tr r 11 d-.12

    (2) i t qat rd, jct ca xt dffrt frta. Fr xa, f a d ctr t at a at t rtca t, t tra tr t t ta.T dcat tat t artc xt a a d ad a a a at

    t a t.

    2,13

    (3) T a artc ca t dffrt drct at ta t.13

    (4) ojct ar t jt t. i fact, t qat rdct- tc qat c rk f a jct dcrda a a rcta f rat f r. T jct t t t t rd.13

    (5) At t qat , t act f rat c ttc, a rat ar a. T crtatrc tat tat ca r t t r t ct f aartc t t t. Fr tac, f t a t at a artct dtr t t, t r ra t t t xact -t. hr, r tat a t t ca t ctf t jct. Fr t ra, t qat rd, ca kt r ct t t t.13

    (6) s t ca fatr ta t d f t.13

    i rt, t qat ad a f caca c d taa rk t qat rd ad c ra.

    OBJECTiVET jct f t td a t tt t t tat t

    CX2 rtad ac t aac , xt, ad trt ft ar t. T tt r dd t cca aat tartcat rt aac, trt, ad xt.

    METHODT td ctd f 81 artcat. i gra, t artc-

    at r att rcrtd fr t ractc f Jdr Cark, mD, hat. i Frda, t artcat r rcrtd fr t t-dt ad fact f Dr p h sc orad. T artc-at r t rqrd t ct ac tt. A a rt, tr rt 81 artcat ac tt. T td a a -d, ac-

    ctrd tt. T dffrt t f rtad r rdd. ot a card, ad t tr a ac. bd a acc-d cr a rca cd ac rtad t dffr-tat t t t t. T artcat ad a t tatr r dd dr t tra, c a -d tt.T trc r cat ard a crrt ar- dc, t ffct ca ard.2,7 mar t ffct tr f t td.

    ProtocoNo.1T rtc ctd f tr tt fr xt. i t tt,

    t rtad a d t artcat t a f tr t

    rt r ft ad.partcat r rqrd t d t xrc tr t rr t t rcrdd tt rdr t trtc. A c rrd, a c affct t d r . Tr trar d: tt a rtad, a cd t a rtad, ad atrd tt a rtad. A ccf tt rt cdd acra xt fr tra 1 t 2 ad a dcra xt frtra 2 t 3. it a azd t t artcat tat t xrca t t t t x. it a rtat t rat txact a ffrt a tr tra t t a accrat dffrc rad- t tra. Exercse1:ToeTouch.partcat at t r t

    xtdd, k ckd, t t , ad ft rad t. Ata ar a acd t t xtd fr at tk t 12 at t ft. T tatr td t d f tta ar t rt t fr d dr t tt. Repetition 1. T artcat tcd a far d t taar a t t dd r f tr ad. hadr acd ttr tat t dx r ac ad racdat t a dtac. T rt r rcrdd. Repetition 2.A CX2 rtad a acd t a f trad, ad t rc a ratd. T rt r rcrdd. Tt art r tractd ad rcrdd c. Repetition 3.T rtad a rd, t tt a ratd r t, ad t rt r rcrdd. T trd ar-t a tractd fr t cd ad t rt r rcrdd.Fxt a xctd t dcra. Frt- f t artcat ddt a qc f tt ad art t t tadt, rac tard t rd fr a t tc.

    Exercse2:HeadTurn.A tr f ak ta a acd tr arxat 18 t 24 fr ad ara t t a. A c f ta a acd t a at ct . T ta aarkd 3- crt fr arxat 4 ft. T artcattd t tr ack t a ad t t ta . nxt, t artc-at t a t tr c ad xtdd a dx r t a frt f t . T dx r a d a a ark ad.

  • 7/28/2019 Teste Dublu Orb

    15/20

  • 7/28/2019 Teste Dublu Orb

    16/20

    14 ALTERNATIVE THERAPIES supplement wrtad std

    r d d a t 1, ad t frc dd t r trar 6 a rcrdd. Step3.A CX2 rtad a acd t t c adrat. T artcat ar r d d 6 , a t1, ad t frc dd a rcrdd. it a atcatd tat t frcdd t t ar d d t 2 ad drtr t t ra t 3.

    ProtocoNo.3T tt ar rt, c a dcatr f ra a-

    ac r .7 A tt dc a Fr 1 a d. C r rd fr ard t artcat. it a a-zd t t artcat tat t xrc a t t ttrt ad tat t a rtat t rdc t xact a ffrt a t rdr t r a tta dffrc t tra.A ccf tt dtratd a cra t frc rqrd tca f aac t tra 1 ad 2. Step1. A rtad a t d. T artcat td rctt ttr ad t t rad. eac artcat rada trr/ t t rt ar (Fr 3) ad ckd t . Txar d a c t t artcat rt ar.prr a ad ad rada t t a accrat rad.T frc dd t ca t artcat t tr aac arcrdd. Step2.A CX2 rtad a acd t t f t artcatft ft, ad t a qc a ratd. T frc dd tca f aac a rcrdd. A atrk a acd aftr tdata f a artcat dr/ar a a aftr a rt f 5 r r. Data r dcardd f a artcat dd t a ttrt t artcat tr t f t aac tt. hr, f tartcat a a dtrat rt f at at a 5-t t fr t ar a a, t data r ctd.

    StudySettngT td a cdctd Jaar tr Frar f 2011 at

    t dffrt cat: w mdc, hat, gra, DrJdr Cark ad Dr p h sc, orad, Frda, Drla mar.

    Varabespartcat rad a fr tar t t dr, 12 t 76

    ar. T a ra ad x ard ca a art cardt artcat t ad tt rtad art t tatartcat, t t tr a r. Fxt a tt artcatard, t xt dcra a a f t artcat crad.

    DataSources/MeasurementFrc art a d t a iada sr Fb Frc

    ga (ndc-s Arca, Crrat, itaca, i).

    Basba ccrrd t artcat ad t t

    ca rdr t t r rad. T ctr t a, ttatr rd tat ac artcat t a qa d-trtd ac ft fr a art.

    w t t rcta f ac ffct, ctrtfactr a t artcat dr t crat ratr ta jtxrt t a ffrt ac t. A f r art ca- ar a rt f t dr dr t a.

    w t frc a, t frc d adtad crad. sdd t ca a t rad rart.

    StudySzeet- artcat r ttd; 46 r fa, ad 35

    r a.

    Partcpantsicar crtra r t f: a ad fa ad

    fr 12 t 76 ar r a t frd ct ad ad tr f a r jr dr, ar, r . p t atr f art r r a tr dca cdt tat ca araatd ca xrt; rat fa; a r takcrtctrd, a dcat, atfaatr dcat, dcat, c raxat, tc, dat, r t-at; ad t a f-rt atd ctrc dcr xcdd fr artcat.

    DiSCUSSiONT rt dtrat tat t CX2 rtad rd

    artcat xt ad aac ad t affctd tr rac-t t c emF radat.

    T jct f t t tt t r r dffrt. T grajct (Ta 1) r rar dr ad dr a dctr car. TFrda jct (Ta 2) r rar c tdt rd ca at. bca f t, xctd tt crratcar t a ad tadard dat f r t ttr. T rd t tr.

    FiGURE3.baac Tt prcdr

    Puey

    Gage

    Handoop

  • 7/28/2019 Teste Dublu Orb

    17/20

    ALTERNATIVE THERAPIES Supplement 15wrtad std

    A xctd, t r Frda r a r x tat dr r ad a dtratd r xt t cardrtad r. i t aac tt, t dr r d ra a . A a rt, xctd tat r t ardr t t rad dtrat a r a ad tadard dat ta t -r-t Frda r. T trt tt a a t xctd, tat t ara frc rqrd t t ar f t dr grar t rqrd 6 a r ta t r Frda r. it td, t ac r r a z card t tr t card rtad. o t-f-t-rdar rt tac r cd act t a ad tadard dat tatr c r ta t d t r card rt-ad.

    T tt f t td a t t car jct tatr t t dtct a ca rfrac fr ac f t -jct, dda, tr t cr f ac xrc t ad t-t t rtad. Tat at ad t rcrt c a art f

    jct tt k t rt. T rar jct a a-r t jct ad a/fa crtra ratr ta qatft cc ca rfrac.

    T trtc xrc (t tc, ad tr, ad drtr) r t t dfct t accrat ar ca -t f , k, ad d at t at a c t a-rt. A ta t t rcdr a xa t rtacf rfr t xrc xact t a a fr ac rtt.T atr f t ad a t t d t t ac rat t xrc.

    T aac tt a a ar f rt r acr d ta c.11 it a ar f t at f frc t tak t t r ar tad rct. T tt a r ccf ad tjct data. T gra tt ctr dtratd a 95% c-c rat t card rtad (Ta 3) card t 25% ac,ad t Frda tt ctr rrtd a 88.2% cc rat tcard rtad card t 38% ac (Ta 4). scc

    TABLE 1: gra st Rt

    Protoco Test Band Mean Standard Devaton

    1 T tc Card 1.02 1.46

    pac 2.93 7.38

    sdr tr Card 5.15 4.28

    pac 5.40 2.94

    had tr Card 4.80 4.44

    pac 9.20 5.91

    2 baac Card 14.29 8.15

    pac 0.17 3.70

    strt Card 7.33 6.26

    pac 1.00 8.00

    TABLE 2: Frda st RtProtoco Test Band Mean Standard Devaton

    1 T tc Card 1.15 1.98

    pac 0.17 1.4

    sdr tr Card 7.23 4.73

    pac 5.53 5.45

    had tr Card 6.94 5.9

    pac 5.11 4.77

    2 baac Card 6.35 15.17

    pac 3.69 6.81

    strt Card 3.72 3.1

    pac 0.61 3.98

    TABLE 3: gra st scc Rat

    ChargedBraceet Pacebo

    prtc Tt sccf tt Tt scc rat sccf tt Tt scc rat

    1 T tc 15 21 71% 2 8 25%

    sdr tr 15 26 58% 2 5 40%

    had tr 23 28 82% 3 5 60%

    2 baac 20 21 95% 2 8 25%

    strt 14 18 78% 1 5 20%

    nt: i rtc 1, tr tra r d: tt a rtad, a cd t a rtad, ad a trd tt a rtad. A ccf ttrt a a cra xt fr tra 1 t 2 ad a dcra xt fr tra 2 t 3. i rtc 2, t 1 t 2 d t atffct f t ctratc d f c , ad t 2 t 3 d t at f t CX3 rtad t ctract tat ffct. A ccf tta a dcra trt t t 1 ad 2 ad a cra trt t t 2 ad 3.

  • 7/28/2019 Teste Dublu Orb

    18/20

    16 ALTERNATIVE THERAPIES supplement wrtad std

    TABLE 4: Frda st scc Rat ChargedBraceet Pacebo

    prtc Tt sccf tt Tt scc rat sccf tt Tt scc rat

    1 T tc 8 13 81% 2 6 33%

    sdr tr 25 30 83% 5 19 26.4%

    had tr 11 16 69% 5 9 69%

    2 baac 15 17 88.2% 5 13 38%

    strt 13 16 81.25% 4 9 44.4%

    nt: i rtc 1, tr tra r d: tt a rtad, a cd t a rtad, ad a trd tt a rtad. A ccf ttrt a a cra xt fr tra 1 t 2 ad a dcra xt fr tra 2 t 3. i rtc 2, t 1 t 2 d t atffct f t ctratc d f c , ad t 2 t 3 d t at f t CX3 rtad t ctract tat ffct. A ccf tta a dcra trt t t 1 ad 2 ad a cra trt t t 2 ad 3.

    t ca a rcrdd ratr frc a rqrd t ca ttt artcat t aac t tra 1 ad tra 2 (, ttad t t t rtad). it a a t tt tat artcatcd a f t ffct f t rtad. T a tat artc-at cd a f c r ta t r ad c r frc a rqrd t ak t t t t d, f tcd td at a.

    T trt tt a a r ccf ad t jctdata. T cad t a trt tt, t a acta a ar-t f t rtad t rc t ffct f xtractratc frc tat ak t d. T ad a r cc rat t a r ac rat, a dtratd t 78%ad 81.25% cc rat t t tra ctr (Ta 3 ad 4).scc t tt a rcrdd t dcra ardtrt rtac t rxt f t c card tr art tt t c , t qtcrad trt rtac t ad rtad.

    Tr a a ac rat t xt tt, t t rdt r dfct t rrdc ac rtt xact t a aa t r rtt. T aac ad trt tt r rt ad r t at t t fr art.

    T td dtrat t rt trt, x-t, ad aac f t artcat t CX2 rtad.D dd td t arr r f artcat ar ddt cr t ffct ad f f t CX2 rtad.

    Acknowedgementsw d k t tak Jat had, pA, ad la mar, edD, d atr data.

    REFERENCES1. bckr R, sd g. The Body Electric: Electromagnetism & The Foundation of Life. n yrk, ny:

    wa mrr & C; 1998.2. Da C. The Subtle Body: An Encyclopedia of Your Energetic Anatomy. bdr, Co: sd Tr

    ic; 2009.3. n atr td. Q. wkda. tt://.kda.r/k/Q. Accd octr 6, 2011.4. ya es, l pw, n b, l g. Act C dc ad catc dc f acc-

    tr .Pugers Arch. 2011 [ aad f rt].5. oca Jl, prt C.Energy Medicine: The Scientic Basis. n yrk, ny: Crc lt;

    2000.

    6. J-m y. The Root of Chinese Chi Kung: The Secrets of Chi Kung Training. 3rd d. Rda,mA: yaa ya marta Art Acat; 1989.

    7. ed D, Ft D. Energy Medicine: Balancing Your Bodys Energies for Optimal Health, Joy, &Vitality.n yrk, ny: Tarcr; 2008.8. gat l. Tai Chi: The Supreme Ultimate. bt, mA: wr bk; 1981.9. n atr td. hrac data tra. wkda. tt://.kda.r/k/

    hrac_data_tra. Accd octr 6, 2011.10. Tr wA. wat ar t r?J Sci Explor.1993;7(3):293-304.11. gr b. The Elegant Universe: Superstrings, Hidden Dimensions, and the Quest for the Ultimate

    Theory.n yrk, ny: ww nrt; 1999.12. gr b. The Fabric of the Cosmos: Space, Time and the Texture of Reality.n yrk, ny: vta

    bk; 2005.13. hak D. Power vs. Force: The Hidden Determinants of Human Behavior. Carad, CA: ha

    h ic; 2002.

  • 7/28/2019 Teste Dublu Orb

    19/20

    ALTERNATIVE THERAPIES Supplement 17Ft Rx Crar Artr Da

  • 7/28/2019 Teste Dublu Orb

    20/20


Recommended